Epigenetics Market is expected to reach US$ 35.84 Billion by 2031

Kits and Reagents Segment to Lead Epigenetics Market Based on Products and Services During 2025–2031

According to our new research study on “Epigenetics Market Forecast to 2031 – Global Analysis – by Products and Services, Application, Technology, and End User,” the epigenetics market size is expected to grow from US$ 11.12 billion in 2024 to US$ 35.84 billion by 2031; the market is expected to register a CAGR of 18.3% during 2025–2031. Major factors driving the epigenetics market growth include the rising global prevalence of cancer, advancements in epigenetic technologies, and the expanding role of personalized medicine.

Epigenetics‍‌ refers to the mechanisms that can be passed down from generation to generation and that regulate gene expression without changing the DNA sequence, usually being affected by factors such as the environment, lifestyle, or the organism's development. The integration of AI and machine learning in epigenetic analysis and advancements in CRISPR-based epigenome editing technologies are expected to be a major epigenetics market trend in the coming years.

Epigenetics Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Epigenetics Market Analysis Based on Segmental Evaluation:

Based on products and services, the epigenetics market is segmented into kits and reagents, instruments and accessories, enzymes, and services. In 2024, the kits and reagents segment held a significant epigenetics market share. The segment forms the backbone of the epigenetic technologies market, enabling precise analysis of gene expression modifications such as DNA methylation, histone acetylation, and chromatin remodeling without altering the underlying DNA sequence, driven by surging demand for tools that enable precise analysis of epigenetic modifications. This segment is pivotal for both research and diagnostic applications, particularly in oncology, neurology, and personalized medicine, where epigenetic biomarkers aid in early disease detection and targeted therapies. High-quality reagents and kits are crucial for accurate and reliable epigenetic analysis and research in academic, clinical, and industrial settings. Kits include bisulfite conversion kits for methylation profiling, ChIP-sequencing kits for histone studies, and RNA sequencing kits for transcriptomic insights. Reagents are crucial in antibody binding, supporting analytical processes, and synthesizing targeted molecules. They are available in various grades, each tailored for specific applications and possessing distinct properties. In epigenetics, reagents are essential for activities, including DNA methylation, RNA transcription, histone modification, DNA purification, PCR, and assays. QIAGEN's EpiTect Bisulfite Kits are widely used for quantitative methylation analysis in cancer research, and Thermo Fisher Scientific's histone modification antibodies and reagents support high-throughput assays.

Various reagent suppliers are gaining significant traction amid rising tariffs and supply?chain concerns. In August 2025, Reuters reported that Chinese pharma research and development firms are sourcing reagents from domestic players, driven by cost pressures, supply reliability needs, and tariffs that peaked at 125% in April 2025. Domestic reagents offer lower cost, faster delivery, and reduced exposure to tariff risk, key in fast?paced research and development environments. Western multinationals such as Merck, Roche, and Thermo Fisher respond by expanding local production facilities in various countries.

The scope of the epigenetics market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the epigenetics market share in 2024.

The US is the leading force in the North American Epigenetics market growth, characterized by a large-scale research base, ample financing, and bright and groundbreaking implementations such as in oncology, neurology, and personalized medicine. As a country eager to convert the epigenetic findings into healthcare, the US is home to a crowd of leading universities, government projects, and private ventures that are pushing the boundaries of the field. The National Institutes of Health (NIH), which has been instrumental in financing through the Common Fund Epigenomics Program, an initiative that funded the epigenetic landscape across the genomes, and then moved to the comprehensive approach across the NIH institutes. The National Cancer Institute (NCI) also contributes heavily by steering the research epigenomics roadmap for cancer risk prediction, early diagnosis, and precision therapy, and, for instance, research on DNA methylation biomarkers for primary liver cancer.

There have been more than 6,385 research works in epigenetics, which are registered at PubMed, and are related to the US. As far as money goes, one may grant unique research projects up to a million-dollar level; the University of Georgia, for instance, was awarded US$1.44 million by NIH for its epigenetics and cancer research program. Moreover, a plethora of clinical trials are being carried out, with many involving epigenetic drugs such as those that have been estimated to be 110 trials for HDAC inhibitors in solid tumors and 128 in hematologic malignancies, which include tumours, and research into the ethical issues involved in public communication about epigenetics.

On the other hand, there are the epigenetic clocks that are able to link aging-related health outcomes worldwide with the US-led research work, which has been published in The Journals of Gerontology. To what commercial ventures, the US is home to almost 57 epigenetics-driven companies, among which are promising young enterprises as Chroma Medicine, which has raised a round of US$125 million for editing the epigenome for therapies raising and Syros Pharmaceuticals, which focuses on generating genomic insights for more efficient drug discovery in epigenetics. There are the other four, EpigenCare, providing personalized epigenomics test services by SKINTELLI-based DNA methylation analysis, and Fulcrum Therapeutics, employing computing tools for drug development. The University of Michigan's Epigenomics Core is an example of a service provider for genome-wide and locus-specific analyses, which is a platform suitable for both academic and industry-based research.

This ecosystem nurtures advancement from the lab to the pockets of marketable diagnostics and treatments, thus making the US the center of epigenetic progress when a great transition of disease mechanisms away from genes is under way.

Promega Corp, Abcam Plc, Oxford Nanopore Technologies, QIAGEN NV, Thermo Fisher Scientific Inc., Merck KGaA, Revvity Inc., Active Motif, EpiGentek Group Inc., and Agilent Technologies Inc. are among the leading companies profiled in the epigenetics market report.

Based on products and services, the epigenetics market is segmented into kits and reagents, instruments and accessories, enzymes, and services. By application, the market is bifurcated into oncology and non-oncology. By technology, DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-Seq), Cleavage Under Targets and Tagmentation (CUT and Tag), Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq), Histone Modification Analysis, RNA Epigenetics, Single-cell Epigenomic Assays, and Others. By end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, and others. In terms of geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of APAC), South and Central America (Brazil, Argentina, and the Rest of SAM), and the Middle East and Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East and Africa).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com